BR0314828A - Inibidor potente de serina protease de hcv - Google Patents
Inibidor potente de serina protease de hcvInfo
- Publication number
- BR0314828A BR0314828A BR0314828-9A BR0314828A BR0314828A BR 0314828 A BR0314828 A BR 0314828A BR 0314828 A BR0314828 A BR 0314828A BR 0314828 A BR0314828 A BR 0314828A
- Authority
- BR
- Brazil
- Prior art keywords
- protease inhibitor
- hcv
- serine protease
- hcv serine
- compound
- Prior art date
Links
- 229940122055 Serine protease inhibitor Drugs 0.000 title abstract 2
- 101710102218 Serine protease inhibitor Proteins 0.000 title abstract 2
- 230000003389 potentiating effect Effects 0.000 title abstract 2
- 239000003001 serine protease inhibitor Substances 0.000 title abstract 2
- 239000000126 substance Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000010076 replication Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000010200 validation analysis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
"INIBIDOR POTENTE DE SERINA PROTEASE DE HCV". A presente invenção refere-se a composições farmacêuticas, kits e métodos de tratamento e prevenção de infecções virais Hepatite C (HCV) em que o Composto (1), um inibidor potente de serina protease de HCV ou um sal farmaceuticamente aceitável do mesmo, é administrado em uma faixa de dosagem selecionada fórmula 1: Também descrito é o uso de um composto da fórmula (1) ou um sal farmaceuticamente aceitável do mesmo, como uma substância de controle para validação de um ensaio de replicação de HCV e também como uma substância de controle para determinação da eficácia relativa de uma ou mais substâncias, sozinhas ou em combinação, para inibir a replicação do HCV.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41494002P | 2002-09-30 | 2002-09-30 | |
US42190402P | 2002-10-29 | 2002-10-29 | |
US43383402P | 2002-12-16 | 2002-12-16 | |
US44366203P | 2003-01-30 | 2003-01-30 | |
PCT/US2003/030402 WO2004030670A1 (en) | 2002-09-30 | 2003-09-25 | Potent inhibitor of hcv serine protease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0314828A true BR0314828A (pt) | 2005-08-02 |
Family
ID=32074646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0314828-9A BR0314828A (pt) | 2002-09-30 | 2003-09-25 | Inibidor potente de serina protease de hcv |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040138109A1 (pt) |
EP (1) | EP1549311A1 (pt) |
JP (1) | JP2006505618A (pt) |
KR (1) | KR20050053709A (pt) |
CN (1) | CN1684683A (pt) |
AU (1) | AU2003278967A1 (pt) |
BR (1) | BR0314828A (pt) |
CA (1) | CA2500259A1 (pt) |
CO (1) | CO5550459A2 (pt) |
EA (1) | EA200500406A1 (pt) |
EC (1) | ECSP055689A (pt) |
MX (1) | MXPA05003365A (pt) |
NO (1) | NO20052130L (pt) |
PL (1) | PL375486A1 (pt) |
TW (1) | TW200412960A (pt) |
WO (1) | WO2004030670A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268391A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
US7642235B2 (en) * | 2003-09-22 | 2010-01-05 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1687021B1 (en) | 2003-11-20 | 2013-11-06 | Boehringer Ingelheim International GmbH | Method of removing transition metals, especially from metathesis reaction products |
EP1730167B1 (en) * | 2004-01-21 | 2011-01-12 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
US20100017895A1 (en) | 2005-07-18 | 2010-01-21 | Amy Weiner | Small animal model for hcv replication |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
CA2618682C (en) | 2005-08-12 | 2011-06-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
NZ568135A (en) | 2005-10-11 | 2011-06-30 | Array Biopharma Inc | Macrocyclic compounds and methods for inhibiting hepatitis C viral replication |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
MX2009000882A (es) | 2006-08-17 | 2009-02-04 | Boehringer Ingelheim Int | Inhibidores de la polimerasa virica. |
NZ581606A (en) * | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) * | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
MX2010006210A (es) | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Inhibidores de serina proteasa de hcv de tripeptido fluorado. |
NZ585370A (en) | 2007-12-19 | 2012-09-28 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
AU2010203656A1 (en) | 2009-01-07 | 2011-07-21 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of HCV and HIV infection |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
MX2011012155A (es) | 2009-05-13 | 2012-02-28 | Enanta Pharm Inc | Compuestos macrociclicos como inhibidores del virus de hepatitis c. |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
SI2618831T1 (sl) | 2010-09-21 | 2016-06-30 | Enanta Pharmaceuticals, Inc. | Makrociklični inhibitorji proteaze HCV na osnovi prolina |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
-
2003
- 2003-09-16 US US10/663,220 patent/US20040138109A1/en not_active Abandoned
- 2003-09-25 WO PCT/US2003/030402 patent/WO2004030670A1/en not_active Application Discontinuation
- 2003-09-25 CA CA002500259A patent/CA2500259A1/en not_active Abandoned
- 2003-09-25 AU AU2003278967A patent/AU2003278967A1/en not_active Abandoned
- 2003-09-25 JP JP2005500319A patent/JP2006505618A/ja active Pending
- 2003-09-25 EP EP03770478A patent/EP1549311A1/en not_active Withdrawn
- 2003-09-25 PL PL03375486A patent/PL375486A1/xx unknown
- 2003-09-25 EA EA200500406A patent/EA200500406A1/ru unknown
- 2003-09-25 MX MXPA05003365A patent/MXPA05003365A/es unknown
- 2003-09-25 KR KR1020057005439A patent/KR20050053709A/ko not_active Application Discontinuation
- 2003-09-25 BR BR0314828-9A patent/BR0314828A/pt not_active Application Discontinuation
- 2003-09-25 CN CNA038234297A patent/CN1684683A/zh active Pending
- 2003-09-29 TW TW092126847A patent/TW200412960A/zh unknown
-
2005
- 2005-03-18 EC EC2005005689A patent/ECSP055689A/es unknown
- 2005-04-26 CO CO05039556A patent/CO5550459A2/es not_active Application Discontinuation
- 2005-04-29 NO NO20052130A patent/NO20052130L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EA200500406A1 (ru) | 2005-12-29 |
EP1549311A1 (en) | 2005-07-06 |
WO2004030670A1 (en) | 2004-04-15 |
CA2500259A1 (en) | 2004-04-15 |
KR20050053709A (ko) | 2005-06-08 |
ECSP055689A (es) | 2005-07-06 |
CN1684683A (zh) | 2005-10-19 |
NO20052130L (no) | 2005-04-29 |
MXPA05003365A (es) | 2005-06-22 |
JP2006505618A (ja) | 2006-02-16 |
US20040138109A1 (en) | 2004-07-15 |
AU2003278967A1 (en) | 2004-04-23 |
PL375486A1 (en) | 2005-11-28 |
CO5550459A2 (es) | 2005-08-31 |
TW200412960A (en) | 2004-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0314828A (pt) | Inibidor potente de serina protease de hcv | |
BR0307524A (pt) | Composição farmacêutica para inibidores de protease viral de hepatite c | |
BR0113666A (pt) | Inibidores da protease peptidomimética | |
BRPI0409068A (pt) | composições farmacêuticas para inibidores de protease viral de hepatite c. | |
BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
BRPI0612104A8 (pt) | composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente | |
BRPI0516825A (pt) | inibição da protease ns3-ns4a do vìrus da hepatite c (vhc) | |
DE60132975D1 (de) | Neue substanzen und verbindungen als protease-inhibitoren | |
BRPI0517463A (pt) | inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos | |
ATE538797T1 (de) | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon | |
ES2169880T3 (es) | Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c. | |
BR0315166A (pt) | Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento | |
BR0206614A (pt) | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto | |
BRPI0418270A (pt) | métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica | |
EA200601467A1 (ru) | Макроциклические соединения в качестве ингибиторов вирусной репликации | |
NO20040547L (no) | Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse. | |
BRPI0519567A2 (pt) | heterociclos tricÍclicos, sua fabricaÇço e uso como agentes farmacÊuticos | |
BRPI0515896A (pt) | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus | |
BR0316771A (pt) | Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica | |
BR0314763A (pt) | Tratamento de infecções fúngicas | |
NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |